GlassScriptPhysician profile
Nitin K Patel
NPI 1669465357
$15,267.23
in general payments reported to CMS, 2019-2025
60 companies · $2,719 in 2025
The $2,719 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,594 · 2020: $1,539 · 2021: $1,826 · 2022: $2,166 · 2023: $2,887 · 2024: $2,536 · 2025: $2,719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,141.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,609.97 | 2019-2025 | |
| Novo Nordisk INC | $1,314.25 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,300.88 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $889.71 | 2019-2025 | Mounjaro, Emgality, Jardiance |
| Merck Sharp & Dohme LLC | $718.08 | 2019-2025 | Verquvo, Belsomra, Dificid |
| Amgen INC. | $671.91 | 2019-2025 | Otezla, Repatha, Otezla |
| Amarin Pharma, INC. | $600.46 | 2019-2023 | |
| Glaxosmithkline, LLC. | $484.95 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $472.69 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Pfizer INC. | $452.82 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $418.33 | 2022-2025 | Rexulti |
| Abbott Laboratories | $378.91 | 2020-2025 | Freestyle Libre 3 |
| Supernus Pharmaceuticals, INC. | $369.75 | 2019-2023 | Qelbree |
| Sanofi-Aventis U.S. LLC | $344.54 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $332.68 | 2019-2024 | Xarelto |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nitin Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.